RxDoctor Payments Data

Thomas Gearhard, MD

Family Medicine · Austell, GANPI 1538159603

Payments from drug & device makers

$974in general payments, 2019–2025

Across 63 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$179
  • AstraZeneca$172
  • Pfizer$110
  • Novo Nordisk$93
  • Boehringer Ingelheim$87
  • Lilly USA, LLC$77
  • plus $256 from 14 others

What the payments were for

  • Food & beverage$96199%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$974 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$153,684
Medicare patients
383
Services billed
1,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$194,860
JanuviaSitagliptin Phosphate73$100,979
EliquisApixaban87$88,899
TrulicityDulaglutide67$83,982
JardianceEmpagliflozin76$60,061
XareltoRivaroxaban61$50,097
FarxigaDapagliflozin Propanediol41$45,663
XifaxanRifaximin11$41,689
ProliaDenosumab17$29,031
MounjaroTirzepatide18$24,806
Bydureon BciseExenatide Microspheres15$15,387
Repatha SureclickEvolocumab21$13,293
MyrbetriqMirabegron15$9,579
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$9,170
InvokanaCanagliflozin14$8,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$194,860192 claims
Lilly USA, LLCTrulicity, Mounjaro$77$108,78885 claims
MerckJanuvia, Belsomra$15$106,44185 claims
PfizerEliquis$110$88,89987 claims
Boehringer IngelheimJardiance$87$60,06176 claims
AstraZenecaFarxiga$172$45,66341 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$23$41,68911 claims
AmgenProlia$179$29,03117 claims
Astellas Pharma US IncMyrbetriq$18$9,57915 claims
GSKArnuity Ellipta$15$1,95112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →